Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director | August 06, 2026 | August 11, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director · CEO | March 04, 2019 | March 04, 2019 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | June 04, 2021 | June 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date August 06, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 400 |
Reported balance
After 2026-08-06 transaction · row 1
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 400 · Balance 400 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Exercise / conversion · Disposed 400 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2: On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
Emergent BioSolutions Inc.
Report date March 04, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 142,617 |
Reported balance
After 2019-03-04 transaction · row 1
1 source rowRow 1 · 2019-03-04 · Sale · Disposed 14,565 · Balance 142,617 F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2: The price reported is the weighted average price. These shares were sold in multiple transactions at prices ranging from $56.74 to $59.66, inclusive. |
| Common StockSEC Table I · non-derivative | IndirectBy Son | 1,936 |
Reported balance
Holding disclosure · report date 2019-03-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,936 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
F2: The price reported is the weighted average price. These shares were sold in multiple transactions at prices ranging from $56.74 to $59.66, inclusive.
F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
REGENXBIO Inc.
Report date June 04, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.52 · Expires 2031-06-04 | Direct | 10,000 |
Reported balance
After 2021-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-04 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest in 12 equal monthly installments following June 4, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in 12 equal monthly installments following June 4, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2018 Filed Mar 1, 2018 22:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (right to buy) · Derivative | 53,485 | $49.64 Strike: $49.64 | $2,654,995.40 |
DisclosureSEC source: 0001140361-18-011280 · doc1.xml · derivative · entry 6 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,485 Underlying: Common Stock · 53,485 shares Expires 2025-02-26 F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,324 | $49.64 | $165,003.36 |
DisclosureSEC source: 0001140361-18-011280 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,552 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 13,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011280 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,876 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 13,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011280 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,505 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,906 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001140361-18-000849 · doc1.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,906 shares Expires 2019-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F5 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 21,906 | $47.91 | $1,049,516.46 |
DisclosureSEC source: 0001140361-18-000849 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,134 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.62 to $48.13, inclusive. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 21,906 | $14.44 | $316,322.64 |
DisclosureSEC source: 0001140361-18-000849 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 21:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001140361-17-046253 · doc1.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,906 Underlying: Common Stock · 20,000 shares Expires 2019-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F5 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 21:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $45.99 | $919,800.00 |
DisclosureSEC source: 0001140361-17-046253 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,134 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.24, inclusive. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 21:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $14.44 | $288,800.00 |
DisclosureSEC source: 0001140361-17-046253 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 21:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001140361-17-041378 · doc1.xml · derivative · entry 7 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,906 Underlying: Common Stock · 20,000 shares Expires 2019-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 21:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,508 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001140361-17-041378 · doc1.xml · derivative · entry 6 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,508 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 21:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $42.92 | $858,400.00 |
DisclosureSEC source: 0001140361-17-041378 · doc1.xml · nonDerivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,134 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.70 to $43.00, inclusive. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 21:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $14.44 | $288,800.00 |
DisclosureSEC source: 0001140361-17-041378 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 21:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 11,508 | $42.50 | $489,090.00 |
DisclosureSEC source: 0001140361-17-041378 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,134 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.47 to $42.78, inclusive. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 21:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 11,508 | $22.03 | $253,521.24 |
DisclosureSEC source: 0001140361-17-041378 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| September 27, 2017 Filed Sep 29, 2017 20:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001140361-17-036963 · doc1.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,508 Underlying: Common Stock · 15,000 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F5 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| September 27, 2017 Filed Sep 29, 2017 20:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 15,000 | $39.92 | $598,770.00 |
DisclosureSEC source: 0001140361-17-036963 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,134 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.85 to $39.98, inclusive. Read SEC document |
| September 27, 2017 Filed Sep 29, 2017 20:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 15,000 | $22.03 | $330,450.00 |
DisclosureSEC source: 0001140361-17-036963 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001140361-17-034333 · doc1.xml · derivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,508 Underlying: Common Stock · 15,000 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 15,000 | $37.21 | $558,150.00 |
DisclosureSEC source: 0001140361-17-034333 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,134 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.14 to $37.27, inclusive. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 15,000 | $22.03 | $330,450.00 |
DisclosureSEC source: 0001140361-17-034333 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001019056-17-000541 · abdunnabi_4.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-31 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 1, 2018. Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0000899243-17-014578 · doc4.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-24 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 24, 2017. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 02:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 10,738 | $31.05 | $333,414.90 |
DisclosureSEC source: 0001140361-17-011680 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,134 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 02:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 8,226 | $30.98 | $254,841.48 |
DisclosureSEC source: 0001140361-17-011680 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,872 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (right to buy) · Derivative | 78,329 | $30.63 Strike: $30.63 | $2,399,217.27 |
DisclosureSEC source: 0001140361-17-010390 · doc1.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,329 Underlying: Common Stock · 78,329 shares Expires 2024-02-27 F4 · derivative.exercise_date: Vests in three equal installments on February 27, 2018, February 27, 2019 and February 27, 2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 6,184 | $30.63 | $189,415.92 |
DisclosureSEC source: 0001140361-17-010390 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,098 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 19,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010390 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,282 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2019 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 19,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010390 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,693 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 01:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option - (Right to Buy) · Derivative | 3,662 | $0.00 Strike: $14.51 | $0.00 |
DisclosureSEC source: 0001140361-17-010111 · doc1.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,662 shares Expires 2017-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc 2006 Stock Incentive Plan, as amended. F2 · derivative.exercise_date: The option vested in three equal installments in March 2011, March 2012 and March 2013. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 01:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 984 | $30.63 | $30,139.92 |
DisclosureSEC source: 0001140361-17-010111 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,105 F1 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc 2006 Stock Incentive Plan, as amended. F4 · shares: Consists of shares withheld from the option exercise and delivered to the issuer to satisfy the reporting persons tax withholding obligations. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 01:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,735 | $30.63 | $53,143.05 |
DisclosureSEC source: 0001140361-17-010111 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,089 F1 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc 2006 Stock Incentive Plan, as amended. F3 · shares: Consists of shares owned by the reporting person and delivered to the issuer to satisfy the reporting persons exercise price for the reported stock options. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 01:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,662 | $30.63 | $112,167.06 |
DisclosureSEC source: 0001140361-17-010111 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc 2006 Stock Incentive Plan, as amended. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 02:59 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to buy) · Derivative | 38,006 | $0.00 Strike: $14.51 | $0.00 |
DisclosureSEC source: 0001140361-17-001760 · doc1.xml · derivative · entry 7 Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,662 Underlying: Common Stock · 38,006 shares Expires 2017-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated prior to the Spin-off. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 02:59 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 28,240 | $31.28 | $883,296.37 |
DisclosureSEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 5 Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,162 F4 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.26, inclusive. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 02:59 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 38,006 | $14.51 | $551,467.06 |
DisclosureSEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| August 01, 2016 Filed Jan 13, 2017 02:59 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherStock Option (Right to buy) · Derivative | 3,662 | $0.00 Strike: $14.51 | $0.00 |
DisclosureSEC source: 0001140361-17-001760 · doc1.xml · derivative · entry 6 Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,668 Underlying: Common Stock · 3,662 shares Expires 2017-03-08 F6 · security: Represents options to purchase Emergent common stock awarded to the reporting person prior to the Spin-off . In connection with the Spin-off, the number of shares and exercise price of the option was adjusted, to preserve the pre-Spin-off intrinsic value of the existing Emergent option award. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Jan 13, 2017 02:59 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,396 F3 · security: In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019. Read SEC document |
| August 01, 2016 Filed Jan 13, 2017 02:59 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 3,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,977 F2 · security: In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018. Read SEC document |
| August 01, 2016 Filed Jan 13, 2017 02:59 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 1,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-001760 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,945 F1 · security: In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in March 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.